ATRC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AtriCure Inc (ATRC) is not a strong buy for a beginner, long-term investor at this time. While the company has shown revenue growth, its declining net income, competitive pressures, and mixed analyst sentiment suggest caution. The lack of strong proprietary trading signals and technical indicators further supports a hold recommendation.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral at 57.823, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its resistance level (R1: 30.745), suggesting limited upside in the short term.
The company reported a 13.05% YoY revenue increase in Q4 2025 and maintains a strong gross margin of 74.97%. Analysts highlight AtriCure's competitive moat and clinical dataset as strengths.
Net income dropped by -111.28% YoY, and EPS declined by -112.12% YoY. Analysts have lowered price targets due to competitive pressures from Edwards Lifesciences and Medtronic. Oppenheimer and JPMorgan downgraded the stock, citing concerns over long-term growth and market share retention.
In Q4 2025, revenue grew by 13.05% YoY to $140.5M, but net income dropped significantly to $1.756M (-111.28% YoY). EPS also fell to 0.04 (-112.12% YoY). Gross margin improved slightly to 74.97% (+0.59% YoY).
Analysts are mixed: Canaccord, UBS, and Citizens maintain Buy/Outperform ratings but have lowered price targets to $52-$55. Oppenheimer and JPMorgan downgraded the stock to Neutral/Perform, citing competitive threats and potential long-term decline.
